Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Primary Aldosteronism: early-phase trial registry
1 of 5 indexed Primary Aldosteronism trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #3,391 of 28,707 conditions by registered trial count.
5 US clinical trials · 1 currently recruiting · #3,391 of 28,707 conditions by registered trial count
Primary Aldosteronism: 5 US clinical trials tracked, 1 recruiting.
Primary Aldosteronism is the subject of 5 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most active sponsor is Brigham and Women's Hospital, running 3 of these trials.
Enrollment posture brief
Registry condition primary-aldosteronism
OPEN 1 | RECR 20% | LATE 1 | EARLY 2 | RANK #3391 | SPON 3
Volume-matched condition peers
Nearest open-share peer: Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive (20% recruiting · 10 trials)
Primary Aldosteronism lists 1 open slots (20% of 5 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Primary Aldosteronism on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Primary Aldosteronism is recruiting below its size-band peers.
1 of 5 indexed trials (20%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Primary Aldosteronism research.
Brigham and Women's Hospital accounts for 3 of 5 trials (60%). 3 distinct sponsors appear on at least one study for this condition label.
-
Most Primary Aldosteronism trials plan to enrol fewer than 100 people.
Median target enrolment is 40 among the 5 trials that report a genuine target (sentinel values excluded). 3 of those (60%) plan for fewer than 100 participants.
-
Primary Aldosteronism research is mostly interventional.
4 interventional and 1 observational studies make up this index (80% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
5 total, page 1 of 1
Cardiovascular Manifestations of MR Activation in Primary Aldosteronism: Pilot Clinical Study
Brigham and Women's Hospital
NCT05030545
Electronic Alert to Improve Testing For Primary Aldosteronism in Patients With Hypertension
Brigham and Women's Hospital
NCT05925569
Predicting Reduction of Hypertension After Adrenalectomy for Primary Aldosteronism: a Multicenter Analysis
UMC Utrecht
NCT04761354
Calcium Channel Blockade in Primary Aldosteronism
Brigham and Women's Hospital
NCT04179019
A Study of CIN-107 in Adults With Primary Aldosteronism
AstraZeneca
NCT04605549
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 2 |
| Phase 4 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Primary Aldosteronism records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Primary Aldosteronism trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Primary Aldosteronism page
5 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 1 Primary Aldosteronism trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Brigham and Women's Hospital sponsors the most Primary Aldosteronism trials on record, review their full trial history before evaluating a specific study. See Brigham and Women's Hospital's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Primary Aldosteronism condition card totals 5 registered trials; most-linked intervention CIN-107 8 mg dosing; top US site state Massachusetts. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.